StockData
CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30

Cencora, Inc.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$340.00−0.92 (-0.27%)

Close on Oct 19, 2026

Market cap
$65.94B
P/E (TTM)
25.2
Dividend yield
0.65%

About Cencora

Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122

Cencora, Inc. sources and distributes brand-name, specialty, and generic pharmaceuticals, over-the-counter medications, and home healthcare supplies for human and animal health. The company also provides commercialization, consulting, packaging, pharmacy automation, and specialty logistics solutions. It operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. Customers include health systems, acute care hospitals, retail and mail-order pharmacies, medical clinics, physician practices, veterinarians, and biopharmaceutical manufacturers.

The company maintains a global presence across the United States, Europe, Canada, and select international markets, supported by a network of distribution centers including a national facility in Columbus, Ohio. Its workforce exceeds 51,000 employees worldwide, with approximately 41% based in the United States. The company is incorporated in Delaware, and the provided text does not specify the city or state of its headquarters.

Summary of the business section of Cencora's latest annual report, written by StockData.

Company profile

Company

Legal name
Cencora, Inc.
Founded
2001
Headquarters
Conshohocken, PA
Address
1 West First Avenue 19428
Phone
(610) 727-7000
Employees
51,000, Sep 30, 2025
Industry
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Incorporated in
Delaware
Fiscal year ends
September 30
Auditor
Ernst& YoungLLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
COR
Exchange
NYSE
Shares outstanding
191M, Jul 31, 2026
Public float
$37.89B, Mar 31, 2025
Filer category
Large accelerated filer
Stock splits
2-for-1, Jun 16, 2009; 2-for-1, Dec 29, 2005; 2-for-1, Mar 25, 1999
SEC CIK
1140859
CUSIP
03073E105
ISIN
US03073E1055
LEI
AI8GXW8LG5WK7E9UD086
EIN
23-3079390

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert P. MauchPresident & CEO, Director69,155
Steven H. CollisExecutive Chairman, Director305,913
Lazarus KrikorianSVP & Chief Accounting Officer16,169
Elizabeth S. CampbellExecutive Vice President19,455
Silvana BattagliaExecutive Vice President23,624
Eva C. BorattoChief Financial Officer3
James F. ClearyChief Financial Officer160,363
Pawan VermaEVP, Chief Data & Info Officer5,148
Lon R. GreenbergDirector17,128
Lauren M. TylerDirector4,456
Ellen CooperDirector893
Dennis M. NallyDirector13,188
Dermot Mark DurcanDirector31,767
Lorence H. KimDirector4,249
Lori RyerkerkDirector1,073
Redonda MillerDirector3,751
Werner BaumannDirector3,687
Frank ClyburnDirector1,724

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Robert P. Mauch
$18.26M$33.89M$6.11M$342$144
FY2024
Robert P. Mauch
$18.48M$61.40M$7.81M$244$156
FY2023
Robert P. Mauch
$17.51M$33.84M$5.09M$193$128
FY2022
Robert P. Mauch
$16.74M$26.07M$4.45M$144$118
FY2021
Robert P. Mauch
$14.87M$39.79M$4.60M$125$123

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of September 30, 2025, we had more than 51,000 employees globally, of which approximately 47,000 were full-time employees and approximately 41% were U.S.-based employees.”

Corporate history

Events identified from SEC filings